Conclusions: For patients receiving NAC, a N 90% reduction in CA-125 was associated with complete IDS, favorable pathologic treatment effect, and decreased need for bowel resection. A preoperative CA-125 b 20 U/mL suggests improved PFS. These findings are helpful for surgical and treatment planning as well as patient counseling. doi:10.1016/j.ygyno.2015.01.104 103 — Featured Poster Session Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? A.E. Garcia-Soto a , J. Java b , W. Nieves-Neira c , M. Markman d , D.K. Armstrong e , J.M. Pearson c . a University of Miami Jackson Memorial Hospital, Miami, FL, USA, b Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, c University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA, d Cancer Treatment Centers of America, Meadowbrook, PA, USA, e Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA Objectives: Intraperitoneal (IP) chemotherapy in optimally cyto- reduced patients with stage III ovarian cancer is associated with a 127.6-month median overall survival. To obtain complete cyto- reduction, radical surgical procedures are often required, which may result in prolonged postoperative recovery and delayed initiation of adjuvant chemotherapy. The aim of this study was to evaluate the impact of the time from surgery to IP chemotherapy initiation (TSIC) on progression-free survival (PFS) and overall survival (OS). Methods: Ancillary review of patients enrolled in Gynecologic Oncology Group (GOG) 172 who received IP chemotherapy was performed. Baseline characteristics were abstracted and patients were stratified according to TSIC. OS and PFS were estimated using the Kaplan–Meier method. The Cox proportional hazards model was used to evaluate independent prognostic factors and to estimate their effect on PFS and OS. A linear model was used to evaluate time from surgery to chemotherapy as a function of baseline variables. TSIC was also analyzed as a categorical variable split near its median. Results: Data from 200 patients treated with IP chemotherapy was reviewed. The median time from surgery to chemotherapy was 26 days (interquartile range: 19–36 days). Time to chemotherapy was not associated with PFS (P = 0.086) or OS (P = 0.470). In a linear model relating TSIC to other clinicopathologic variables, gross residual disease was significantly associated with shorter TSIC (β = −0.263; 95% CI −0.416–0.109; P b 0.001). Using TSIC as a categorical variable, there was no significant difference in PFS or OS between patients who received the first cycle of IP chemotherapy prior to 25 days of surgery and those who received it after 25 days (PFS: P = 0.224; OS: P = 0.524). Conclusions: In this ancillary data study of GOG 172, the time from surgery to initiation of IP chemotherapy did not significantly affect PFS or OS. Prolonged recovery from radical surgical procedures required to achieve complete cytoreduction should not preclude the use of IP chemotherapy. doi:10.1016/j.ygyno.2015.01.105 104 — Featured Poster Session Improvement in rates of cytoreduction to no residual for stages IIIB–IV ovarian, fallopian tube and primary peritoneal cancer: A change in surgical approach and individualized surgeon feedback S.J. Lee, R.S. Suidan, M. Quincy, Y. Sonoda, D.A. Levine, M.M. Leitao, G.J. Gardner, E. Jewell, O. Zivanovic, D.S. Chi. Memorial Sloan Kettering Cancer Center, New York, NY, USA Objectives: To examine the rates of cytoreduction at primary surgery for ovarian, tubal, and peritoneal carcinoma. Methods: All patients with ovarian, tubal, and peritoneal carcinomas at our institution from 1/1/2001 through 12/31/2013 were identified. Only patients who had undergone primary cytoreductive surgery with stage IIIB–IV disease were included. Cases classified as stage IIIC solely by lymph node metastases were excluded. Cytoreductive outcomes were classified as no residual, optimal (residual b 1 cm), suboptimal (residual N 1 cm), and unresectable. Three time periods were selected for comparison corresponding to changes in quality improvement: 2001–2004, incorporation of extensive upper abdominal surgery (group 1); 2005–2010, immediate period after institutional analysis revealed significant survival improvement between no residual and optimal cytoreduction (group 2); and 2011–2013, implementation of anonymous individualized surgeon feedback regarding rates of cyto- reduction (group 3). Clinicopathologic data were collected from the medical record. Appropriate statistical tests were used. Results: In all, 926 patients underwent primary cytoreductive surgery for stage IIIB–IV ovarian, tubal, and peritoneal carcinoma. Median age of the entire cohort was 61 years (range, 19–96 years), body mass index was 25.7 (range, 15.9–58.5) and American Society of Anesthesiologists class 2 (range, 1–4). Primary site of disease was ovary in 695 cases (75%), fallopian tube in 144 cases (16%), and peritoneum in 87 cases (9%). The majority had stage IIIC disease (77%) and serous histology (91%). Over the three time periods, there was a significant improve- ment in rates of cytoreduction to no residual: 28% (63/224) for group 1, 42% (181/432) for group 2, and 55% (148/270) for group 3 (P b 0.001) (Fig. 1). There were no significant differences in rates of carcinomatosis or upper abdominal disease among the three groups. Conclusions: The use of extensive upper abdominal surgery and the implementation of an anonymous feedback system of individual surgeon's cytoreduction rates significantly improved the rate of cytoreduction to no residual. doi:10.1016/j.ygyno.2015.01.106 105 —Featured Poster Session Comparison of dose-dense and every-3-week taxane in the neoadjuvant treatment of ovarian, fallopian tube, and primary peritoneal cancer E.M. Hinchcliff a , I. Wilkinson-Ryan b , A.A. Gockley c , K.M. Esselen a , A.R. Hagemann b , M. Auer d , Y. Tao b , D.G. Mutch b , K.C. Fuh e , N.S. Horowitz f . a Brigham and Women's Hospital/Harvard University, Boston, MA, USA, Abstracts / Gynecologic Oncology 137 (2015) 2–91 45